Interestingly, in preclinical trials, Gal3 blockade in solid tumors together with PD1/PDL1 checkpoint inhibition or T-cell agonists boost an immunologic response against tumors, resulting in tumor regression [88]. This evidence concerns the gene LGALS3 and neoplasm.